We are a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient’s appearance. Our core product, RADIESSE® injectable dermal filler, is designed to provide long-lasting, cost-effective and safe aesthetic improvement for patients. Our clinical studies have demonstrated that RADIESSE® provides meaningful initial aesthetic correction and approximately 12 months’ duration of aesthetic improvement in many patients, resulting in high patient satisfaction. Physicians have used RADIESSE® for more than seven years, and we have shipped over 1,000,000 syringes worldwide. Our strategy is to become a worldwide leader in medical aesthetics by building on our success with RADIESSE® , gaining a market leading position in dermal fillers, and commercializing new products beyond dermal fillers that enhance the practice of medical aesthetics. To expand our portfolio in medical aesthetics, we have obtained licenses to or acquired three products: Polidocanol, a leading sclerotherapy treatment in Europe for varicose veins sold under the trade name Aethoxysklerol® ; BIOGLUE AESTHETIC™ medical adhesive, a Class III medical device currently in clinical testing for tissue fixation in browplasty, or forehead lift; and RELAXED EXPRESSIONS™ System, a radiofrequency 510(k) medical device cleared by the United States Food and Drug Administration, or FDA, for use in creating radiofrequency (RF) heat lesions in nerve tissue, for which we plan to seek FDA clearance for use in the reduction of frown lines in the forehead.
Company profile
Ticker
BFRM
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
14 Apr 10
15-12B
Securities registration termination
18 Mar 10
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Feb 10
25-NSE
Exchange delisting
19 Feb 10
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Feb 10
S-8 POS
Registration of securities for employees (post-effective amendment)
19 Feb 10
SC 14D9/A
Tender offer solicitation (amended)
19 Feb 10
SC TO-T/A
Third party tender offer statement (amended)
19 Feb 10
10-Q
2010 Q2
Quarterly report
16 Feb 10
SC 14D9/A
Tender offer solicitation (amended)
16 Feb 10